Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...
Vertex Pharmaceuticals price target raised to $540 from $522 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
STAT1d
The first shot taken at Medicaid, and Optum’s wellness visit ad
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
Wall Street Journal5d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...